Loxo Oncology's targeted RET drug shows promise in early trial

CHICAGO (Reuters) - An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news